Alivus Life Sciences Q3 FY26 results: revenue up 4.8% YoY, PAT rises 9.7%
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alivus Life Sciences reported Q3 FY26 revenue from operations of 672.89 crore, up 4.8% YoY from 641.84 crore. PAT rose 9.7% to 150.26 crore from 136.96 crore. For nine months, revenue grew to 1,862.72 crore versus 1,737.34 crore, and PAT climbed to 401.82 crore from 343.76 crore. The company booked an exceptional item of 25.66 crore for the statutory impact of new Labour Codes covering gratuity and leave encashment. Auditor Walker Chandiok issued an unmodified limited review report.
Steady YoY growth in revenue and profit despite a one-time labour code charge. Positive earnings momentum for shareholders.